title: Moxifloxacin in the therapy of experimental pneumococcal meningitis.
abstract: The activity of moxifloxacin (BAY 12-8039) against a Streptococcus pneumoniae type 3 strain (MIC and minimum bactericidal concentration [MBC] of moxifloxacin, 0.06 and 0.25 microgram/ml, respectively; MIC and MBC of ceftriaxone, 0.03 and 0.06 microgram/ml, respectively) was determined in vitro and in a rabbit model of meningitis. Despite comparable bactericidal activity, 10 micrograms of moxifloxacin per ml released lipoteichoic and teichoic acids less rapidly than 10 micrograms of ceftriaxone per ml in vitro. Against experimental meningitis, 10 mg of moxifloxacin per kg of body weight per ml reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as ceftriaxone did (mean +/- standard deviation, -0.32 +/- 0.14 versus -0.39 +/- 0.11 delta log CFU/ml/h). The activity of moxifloxacin could be described by a sigmoid dose-response curve with a maximum effect of -0.33 delta log CFU/ml/h and with a dosage of 1.4 mg/kg/h producing a half-maximal effect. Maximum tumor necrosis factor activity in CSF was observed later with moxifloxacin than with ceftriaxone (5 versus 2 h after the initiation of treatment). At 10 mg/kg/h, the concentrations of moxifloxacin in CSF were 3.8 +/- 1.2 micrograms/ml. Adjunctive treatment with dexamethasone at 1 mg/kg prior to the initiation of antibiotic treatment only marginally reduced the concentrations of moxifloxacin in CSF (3.3 +/- 0.6 micrograms/ml). In conclusion, moxifloxacin may qualify for use in the treatment of S. pneumoniae meningitis.
authors.affiliation: Department of Neurology, University of Göttingen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: A
authors.initials: A
authors.lastname: Dalhoff
authors.forename: K
authors.initials: K
authors.lastname: Stuertz
authors.forename: F
authors.initials: F
authors.lastname: Trostdorf
authors.forename: V
authors.initials: V
authors.lastname: Chen
authors.forename: O
authors.initials: O
authors.lastname: Schneider
authors.forename: C
authors.initials: C
authors.lastname: Kohlsdorfer
authors.forename: W
authors.initials: W
authors.lastname: Brück
authors.forename: R
authors.initials: R
authors.lastname: Nau
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001372:Aza Compounds; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D024841:Fluoroquinolones; D008586:Meningitis, Pneumococcal / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D000077266:Moxifloxacin; D011008:Pneumococcal Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism; D011804:Quinolines; D015363:Quinolones / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D013296:Streptococcus pneumoniae / Q000187:drug effects*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015363:Quinolones; D000077266:Moxifloxacin